OOOlga L. Orlova

Olga L. Orlova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga L. Orlova has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Application of a risk-based approach to determine critical parameters of the process of obtaining a lyophilisate based on a derivative of LCS-1269

    by A. V. Lantsova, E. V. Sanarova, O. L. Orlova, A. P. Kolpaksidi, N. A. Oborotova, L. L. Nikolaeva, Z. S. Shprakh

    Introduction. Maintaining the basic quality parameters of a drug is the key to its successful use in clinical practice. Productive use of the results of risk identification and assessment allows us to guarantee the effectiveness and safety of medicines through preventive measures to identify and eliminate potential threats to quality during their development and production. Aim. The aim of the study was to identify critical points in the technological process of obtaining a lyophilized dosage form of a compound from the class of indolocarbazoles LCS-1269 using a risk-based approach. Materials and methods. To analyze the risks in the technology for obtaining a lyophilisate based on LCS-1269, the risk management analysis tools and methods presented in the ICH Q8, Q9, Q10, State Pharmacopoeia of Russia XV ed. and ISO 31000-2019 guidelines were used. Results and discussion. When identifying risks of the production process, the main critical process parameters and critical control points were identified, among which the most important are compliance with the mode of dissolution of the pharmaceutical substance and excipients, filtration of the resulting solution and its lyophilization, as well as control over the main quality indicators characteristic of lyophilized dosage forms for parenteral use. Conclusion. The application of the selected approach made it possible to identify and assess possible risks to product quality at different stages of production of the drug "LCS-1269, lyophilisate for preparation of injection solution 25 mg" and to develop a strategy to eliminate or mitigate these risks and achieve the necessary goals, namely, obtaining high-quality, effective and safe drugs.

  • Open Access

    Primary evaluation of a new 3-hydroxyquinazoline derivative initial – a potential inducer of ferroptosis antitumour activity

    by Ekaterina V. Sanarova, Larisa M. Borisova, Marina P. Kiseleva, Ludmila L. Nikolaeva, Dmitriy V. Gusev, Vasiliy N. Osipov, Olga L. Orlova, Irina S. Golubeva, Anna V. Lantsova

    Background. Ferroptosis, a non-apoptotic, iron-dependent form of regulated cell death in which membrane phospholipid peroxidation products accumulate within the cell, was discovered relatively recently. Numerous scientific publications in recent years indicate that ferroptosis can lead to the tumor cells death that survive chemotherapy. Therefore, ferroptosis as an alternative pathway for cell death raises hope for new opportunities for the modern anticancer drug therapy development and improvement. 3-Hydroxyquinazoline derivatives as ferroptosis inducers are promising pharmacological substances with pronounced ferroptotic activity. Aim. To conduct a preliminary assessment of the new domestic derivative of 3-hydroxyquinazoline (OVF-009), antitumor activity, a potential ferroptosis inducer, in mouse tumor growth models administered via two routes of administration (intraperitoneal and oral). Materials and methods. Original substance OVF-009, excipients (Kolliphor ELP, ethanol 95 %, Kollidon 17 PF, sodium hydroxide, phosphate buffer, etc.); technological methods; immunocompetent mice, tumor models (Lewis lung epidermoid carcinoma, melanoma B-16, cervical cancer CC-5, breast adenocarcinoma Ca-755); biological methods described in the guidelines for drugs antitumor activity preclinical studies. The antitumor effect was assessed by tumor growth inhibition (TGI) of animals treated with OVF-009, compared with animals in the control group. Results. During the technological stage of the work, an OVF-009 oral dosage form based on corn oil was obtained. For intraperitoneal administration, a previously developed solution based on hydrogenated castor oil was used. The result of the experiments on mice tumor models showed the maximum antitumor effect on melanoma B-16 of 75 % TGI on the 8th day after the end of administration, with Lewis lung epidermoid carcinoma, a high but short-term effect of TGI = 84 % on the 1st day with intraperitoneal administration. With per os administration, the best results were obtained with Ca-755 and CC-5: with Ca-755, a significant antitumor effect was shown with TGI = 76–77 % (p 0.05) up to the 8th day after the end of administration; with CC-5, TGI = 73–68 % (p 0.05) was noted from the 8th to the 16th day of observation. Conclusion. The obtained results on the OVF-009 antitumor activity in mouse tumor models indicate the promise of this original substance continuing in-depth preclinical studies.

  • Open Access

    Properties and antitumor activity of combined polymeric nanoparticles based on gefitinib and a photosensitizer

    by Lyudmila L. Nikolaeva, Anna V. Lantsova, Maria A. Baryshnikova, Anna Rudakova, Olga L. Orlova, Natalia D. Bunyatyan, Alina A. Markova, Vladimir A. Kuzmin, Ekaterina V. Sanarova

    Introduction: Gefitinib (GFT) is a moderately lipophilic small quinazoline molecule with proven efficacy in treating locally advanced or metastatic non-small cell lung cancer. Due to the broad activity of GFT and other tyrosine kinase inhibitors, researchers worldwide strive to create various nanoparticles based on these substances, including their combinations with other active molecules. This study investigated morphology, release, and cytotoxic activity of micellar form of combination particles with GFT and a phthalocyanine photosensitizer in various tumor models. Materials and Methods: The micellar model was obtained by mixing/emulsifying the aqueous and organic phases using a continuous flow of nitrogen gas, an aqueous solution of poloxamer 188 as the aqueous phase, and a chloroform solution of the active substances as the organic phase. Conventional analytical and biological methods were used to characterize the obtained micelles. The average particle size and polydispersity index of the samples were determined by dynamic light scattering and microscopy. Release from particles was determined in vitro by quantifying free GFT released through the dialysis insert. Cytotoxic activity was studied on the cell lines of lung cancer NCI-H640, glioblastoma A 172, melanoma A 375, and breast cancer SK-BR-3. Results and Discussion: The micelles with GFT, a photosensitizer, poloxamer 188, and polyvinylpyrrolidone were spherical and nanosized. 50% of the encapsulated GFT was released from the micellar model in a phosphate buffer medium within about 10.0 h. Testing of micelles on a panel of four tumor cell lines in the dose range of 0.1-20 μg/mL showed high cytotoxic activity of the studied model, especially for lung cancer and glioblastoma. Conclusion: The obtained data suggest a promising in-depth study of micellar nanoparticles of GFT with a photosensitizer, especially concerning lung cancer and glioblastoma.

  • Open Access

    Advances in the use of nanomicelles to enhance the efficacy of antitumour substances (review)

    by E. V. Sanarova, L. L. Nikolaeva, S. D. Shceglov, Zh. M. Kozlova, O. L. Orlova, N. A. Oborotova, A. V. Lantsova

    Introduction. The influence of the dosage form on the pharmacological effect has been known since ancient times. The strategy for the preparation of micellar dosage forms for active antitumour substances was formulated in the last century. However, it has become widespread in practice in recent decades. This is largely due to advances in the synthesis of new structural components for the formation of micellar carrier, as well as to the acquisition of better knowledge of biochemical processes occurring in the tumour cell.Text. This review is devoted to the achievements in the field of application of nanomicellar forms of antitumor drugs to improve the effectiveness of cancer therapy, which cover the period from 2019 to 2024. For this purpose, excipients used to obtain nanomicellar forms of antitumor substances are considered and analyzed, using docetaxel, paclitaxel, doxorubicin, and photosensitizers as examples. The creation of micellar forms allowed us to take a new look at these substances known in oncological practice.Conclusion. Available achievements in the field of nanomicelles application for increasing the effectiveness of antitumour substances undoubtedly show the promising development of this technological direction. However, there are still many unresolved issues related to the stability of nanomicelles when administered into the body, as well as legal regulation in the field of creation and introduction of this new pharmaceutical form. These questions still need to be resolved by pharmaceutical science.

  • Оценка эквивалентности таблеток лапатиниба в тесте сравнительной кинетики растворения

    by Зоя Сергеевна Шпрах, Яна Алексеевна Поскедова, Ольга Львовна Орлова, Галина Владиславовна Раменская

    Таблетки лапатиниба, ингибитора тирозинкиназы, широко применяются для лечения HER2-позитивного рака молочной железы. При разработке воспроизведенного лекарственного средства для исследования его биоэквивалентности по отношению к оригинальному препарату проводят тест сравнительной кинетики растворения. Оценка результатов исследования с использованием анализа факторов сходимости/различия (f2 и f1) показала эквивалентность профилей растворения воспроизведенных и оригинальных таблеток лапатиниба в изученных средах (среде контроля качества и буферах со значением pH 1,2 и 4,5).

  • Open Access

    Test Dissolution for quality control of water-insoluble somatostatine analog

    by E. V. Ignatieva, M. N. Kraeva, I. V. Yartseva, D. V. Podymova, O. L. Orlova, D. V. Gusev, Ya. A. Poskedova, T. M. Litvinova, Z. S. Sprakh

    Background. Test Dissolution, which confirms the release of the active substance, is one of the most important criteria for the quality of tablets. This test significance is determined by potential correlation between the drug absorption in vivo and its release from the dosage form. It is especially difficult to develop the test Dissolution for substances that are poorly soluble in water.Aim. To develop a test Dissolution method for cyphetrylin tablets, 60 mg and to study the release of active substance.Materials and methods. In the work we used an original analogue of somatostatin – cyphetrylin, synthesized in the laboratory of chemical synthesis of N.N. Blokhin National Medical Research Center for Oncology of the Russian Ministry of Health. The test was developed for cyphetrylin tablets, 60 mg. The study was carried out on a dissolution tester Erweka series 700 (type II – Paddle (Erweka, Germany), using hydrochloric acid and isopropyl alcohol and their mixture as a dissolution medium. Quantitative determination of released cyphetrylin was carried out on a Agilent Cary® 100 recording spectrophotometer (Agilent Technologies, USA).Results. Optimal conditions were selected to determine the release of cyphetrylin from tablets, 60 mg. Since cyphetrylin is insoluble in water, it is proposed to use a mixture of hydrochloric acid and isopropyl alcohol in a ratio 3:2 as a dissolution medium. It was shown that a paddle rotation speed of 100 rpm provides the release of cyphetrylin normalized quantity into the dissolution medium in 45 min. A method for cyphetrylin assay in a medium by direct spectrophotometry has been developed. Evaluation of the cyphetrylin release profile showed its gradual release from the tablets, which can be described by a linear relationship in accordance with the Higuchi equation.Conclusion. As a result of the research, a test Dissolution procedure has been developed and the release profile of cyphetrylin from tablets, 60 mg, was assessed. Experimental data showed that in the selected conditions cyphetrylin release from the tablets is more than 80 % and meets the requirements of the Russian State Pharmacopoeia XV ed.

  • Open Access

    Obtaining a Water-soluble Form of Hydrophobic Indolelocarbazole Derivative Using Solubilizer Complex

    by A. P. Kolpaksidi, M. V. Dmitrieva, L. L. Nikolaeva, O. L. Orlova, I. I. Krasniuk

    Introduction. LHS-1269 is an indolocarbazole derivative with high antitumor activity. Due to the hydrophobic properties of the active substance, the use of organic co-solvents – dimethyl sulfoxide (DMSO) and ethanol – is required to obtain an injectable dosage form (DP). However, the inclusion of organic solvents in the composition of the DF carries a potential risk of side effects as a result of the use of the drug.Aim. Selection of auxiliary substances for obtaining an aqueous solution of hydrophobic indolecarbazole derivative, which allows minimizing the concentration of organic solvents in the composition of DF.Materials and methods. The object of the study is the active substance LHS-1269 series 010320, produced in the Chemical Synthesis Laboratory of the N. N. Blokhin National Medical Research Center of Oncology. The following auxiliary substances were used to obtain model compositions: Kollidon® 17 PF, Kollisolv® PEG-400, Kolliphor® P 188, Montanox™ 20, DMSO (p.a.), ethanol 95 % (standardized according to pharmacopoeia quality standard ФС.2.2.0019.18 of The State Pharmacopoeia of the Russian Federation). Analytical scales OHAUS Analytical Plus AP 100S and laboratory scales AND DL-120 were used for weighing LHS-1269 and auxiliary substances. The dissolution and mixing of the components was carried out on an IKA® C-MAG HS 4 magnetic stirrer.Results and discussion. In the course of the study, 2 groups of model compositions were obtained and estimated, comprising a complex of two or more auxiliary substances as a solubilizer. The first group of formulations contained DMSO at a concentration of 5 % and ethanol at concentrations from 0 to 15 %. The compositions of the second group included DMSO from 0 to 4 %. As a result, it was found that the addition of 5 % Kolliphor® P 188 to the composition of the solution reduces the content of ethanol to 5 %. In this case, with further decrease in ethanol, turbidity of the solution and precipitation are observed. Reducing the concentration of DMSO in the DF to 2 % was achieved by using a combination of 20 % ethanol and solubilizer complex – Kollidon® 17 (20 %), Kollisolv® PEG-400 (20 %) and Kolliphor® P 188 (5 %). In this case, the total dissolution of the active substance without DMSO was observed when compensating for the organic solvent by introducing additional auxiliary substances – Montanox™ 20 (5 %) and benzene (2 %).Conclusion. As a result of the research, the compositions of the auxiliary substances of solubilizers are selected, allowing to obtain an aqueous solution of the hydrophobic compound LHS-1269 with a minimum concentration of organic solvents.

  • Open Access

    Technological aspects of creating neopeptide vaccines

    by M. V. Dmitrieva, M. A. Baryshnikovа, O. L. Orlova, V. S. Kosorukov

    Personalized neoantigen vaccines are a group of individually designed cancer vaccines that enhance patients’ own antigen-specific immune responses. These include vaccines based on dendritic cells, DNA, mRNA and synthetic peptides. An analysis of 98 clinical trials of neoantigenic vaccines from the ClinicalTrials.gov database found that peptide vaccines are one of the most popular cancer vaccines, accounting for about 50 % of clinical trials. They usually consist of a mixture of long or short peptides, dissolved depending on their properties in an appropriate solvent, and an adjuvant that stabilizes and increases their effectiveness. The most used immunoadjuvants in the formulation of neopeptide vaccines are Toll-like receptor agonists (poly-ICLC) and granulocyte-macrophage colony-stimulating factor. The development of neoantigenic vaccines presents a number of distinctive challenges compared to other types of vaccines. The process should cover and validate the various steps in the development, production and administration processes in order to maximize the efficacy and safety of vaccines. In the technology for the production of peptide vaccines, 3 main stages can be distinguished: 1) screening and identification of neoepitopes using the approaches of computer prediction, co-immunoprecipitation, mass spectrometry and cytotoxic experiments; 2) synthesis of peptides by methods of standard solid-phase synthetic peptide chemistry; 3) actually obtaining a vaccine preparation suitable for storage, transportation and administration to the patient. Taking into account the specificity of the drug, the manufacturing process must be carried out strictly according to the Good Manufacturing Practice standard with mandatory quality control of intermediate and finished products


  • Open Access

    Application of Solid Dispersion Technology to Obtain a Model of Injectable Dosage Form of Indolocarbazole Derivative

    by A. P. Kolpaksidi, M. V. Dmitrieva, O. L. Orlova, L. V. Ektova, I. I. Krasniuk

    Introduction. N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia synthesized an original derivative of indolocarbazole with the carbohydrate residue xylose, which has a pronounced cytotoxic and anti-angiogenic activity. The substance LCS-1269 is an amorphous powder that is almost insoluble in water, which causes difficulties in the development of an injectable dosage form (IDP). To solve this problem, a technological approach to obtain a solid dispersion (SD) of LCS-1269 has been proposed.Aim. To develop a model of IDP of the indolocarbazole derivative LCS-1269 based on SD.Materials and methods. We used a substance LCS-1269 synthesized in the Chemical Synthesis Laboratory of the N. N. Blokhin National Medical Research Center of Oncology. Emuxol 268, Kolliphor® P 188, Soluplus®, Lutrol® F68, Kollidon® 12 and Kollidon® 17, soybean phosphatidylcholine unsaturated S PC and saturated S PC-3 were investigated as carriers of the active substance. SD LCS-1269 was obtained by solvent removal: the active substance was dissolved in acetone, the carrier − in chloroform, the obtained solutions were mixed, transferred into a bottle and evaporated under vacuum (50 ± 5 mbar) in the desiccator at water bath temperature 65 ± 2 °С. To obtain aqueous solution of LCS-1269 dry mass was dissolved using different auxiliary substances or their mixtures: water for injection, ethanol 95 %, benzyl alcohol, Kollisolv® PEG 400, MONTANOX™ 80. To increase stability, the aqueous solution of LCS-1269 was lyophilized in an Edwards Minifast DO.2 freeze dryer.Results and discussion. Kollidon® 17 was chosen as the carrier material for the SD active substance. It was found that a clear solution of LCS-1269 with the concentration of the active substance 0.5 % was formed by dissolving the SD in ethanol 95 % and then gradually diluting the alcohol mixture with water for injection. In this case, the mass ratio of the components of the developed model IDF LCS : Kollidon® 17 : ethanol : water is 1 : 40 : 32 : 127. As a result of freeze-drying of the water-ethanol solution of LCS-1269 the IDF in the form of lyophilizate easily soluble in a 10 % solution of ethanol was obtained.Conclusion. An IDF model of the hydrophobic derivative of indolocarbazole LCS-1269 based on SD was developed and submitted for biological studies to evaluate its effectiveness.


  • Open Access

    Determination of Optimal Technological Conditions for the Process of Production a Liposomal Dosage Form of Cyphetrylin

    by M. V. Dmitrieva, O. L. Orlova, A. V. Lantsova, I. I. Krasnyuk

    Introduction. The Laboratory for the development of dosage forms of the N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russian Federation has developed a composition of an injectable liposomal dosage form based on soybean phosphatidylcholine, a hydrophobic analog of the hypothalamic hormone somatostatin − cyphetrylin, intended for the treatment of neuroendocrine tumors.Aim. Determination of optimal technological conditions for the process of obtaining a liposomal dosage form of cyphetrylin.Materials and methods. The study used the substance cyphetrylin synthesized in the of Chemical Synthesis Laboratory of the N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russian Federation; soybean phosphatidylcholine S PC and polyethylene glycol-2000-distearoylphosphatidylethanolamine, produced by Lipoid GmbH (Germany); cholesterol ≥99 % (Sigma-Aldrich, Japan). For the preparation of phospholipid vesicles loaded with cyphetrylin and "empty", the methods of lipid film hydration with subsequent extrusion or homogenization of the dispersion of multi-layer liposomes were used. The obtained liposomal samples were evaluated by quality indicators − the effectiveness of the inclusion of cyphetrylin in vesicles, their average size and surface charge (zeta potential), the viscosity of the dispersion. To evaluate these characteristics, the methods of spectrophotometry, laser scattering spectroscopy, determination of the electrophoretic mobility of particles and viscometry were used.Results and discussion. It was found that the most suitable organic solvent for obtaining a solution of cyphetrylin and lipid components of the dosage form is chloroform. The duration of the drying period of the lipid film under vacuum to remove the residual solvent is determined by the ratio of the volume of the distillation flask used and the mass of its loading its loading. At the same time, hydration off the lipid film with water for injection should be carried out under conditions of low-pressure and room temperature. To obtain a dispersion of single-layer cyphetrylin liposomes of the required size, an extrusion method using nylon and polycarbonate membranes with a filter pore diameter of 0.22 and 0.2 um, respectively, was chosen.Conclusion. The optimal technological conditions for the process of obtaining a liposomal dosage form in the form of a dispersion of a hydrophobic analog of the hypothalamic hormone somatostatin − cyphetrylin are determined.